Volume 18, Issue 3 (September-2026 2026)                   Iranian Journal of Blood and Cancer 2026, 18(3): 90-101 | Back to browse issues page

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Kamma H S, K M, S S R, K S, D P, R S V, et al . CAR T-Cell Therapy: From Conceptual Breakthrough to Clinical Transformation in Modern Oncology. , Iranian Journal of Blood and Cancer. 2026; 18 (3) :90-101
URL: http://ijbc.ir/article-1-1943-en.html
CAR T-Cell Therapy: From Conceptual Breakthrough to Clinical Transformation in Modern Oncology
Harsha Sri Kamma *1 , Mounika K2 , Sambasiva Raju S2 , Shainisha K2 , Pranathi D2 , Sai Venkat R2 , Sree Charan Ekambarapu3 , Sathish Kumar Konidala4 , Srinivasa Babu Puttagunta5
1- Department of Pharmaceutical Analysis, Vignan Pharmacy College, Vadlamudi, Guntur. AP, India. , hk186909@gmail.com
2- Department of Pharmaceutical Analysis, Vignan Pharmacy College, Vadlamudi, Guntur. AP, India.
3- Department of Pharmaceutical Biotechnology, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, 576140, India.
4- Department of Pharmaceutical Sciences, School of Biotechnology and Pharmaceutical Sciences, Vignan's Foundation for Science, Technology & Research, Vadlamudi, Guntur, 522213, Andhra Pradesh, India.
5- Department of Pharmaceutics, Vignan Pharmacy College, Vadlamudi, Guntur. AP, India.
Abstract:   (11 Views)
Adoptive cellular immunotherapy has evolved into a remarkably potent precision medicine approach that has revolutionized cancer therapy, particularly for hematologic cancers, due to chimeric antigen receptor therapy, or CAR.  The historical development, immunological concepts, CAR architecture, and manufacturing procedure that support the therapeutic potency of CAR T-cell are outlined in this paper. subsequently this study provides an overview of the history, immunological ideas, CAR architecture, and manufacturing techniques that enhance the efficacy of CAR T-cell, emphasizes significant toxicities like cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome, as well as current management approaches, while highlighting the outstanding therapeutic results attained in lymphomas, B-cell acute lymphoblastic leukemia, and multiple myeloma. The paper also looks at therapeutic resistance mechanisms, obstacles to solid tumor efficacy, and new engineering solutions like logic-gated, multi-target, and armored CAR constructs. Lastly, new advances in combination therapy, earlier-line clinical applications, and "off-the-shelf" allogeneic CAR T-cells are being studied as potential methods to enhance accessibility, safety, durability, and broader therapeutic utility. All things considered, CAR T-cell therapy is a groundbreaking development in contemporary oncology that has the potential to fundamentally alter how cancer is treated in the future.
Keywords: Cytokine release syndrome (CRS), Solid tumors, Blood-related cancers, Cancer immunotherapy, Chimeric antigen receptor (CAR) T-cell, Medical therapy, Allogeneic CAR T-cells
Full-Text [PDF 1307 kb]   (2 Downloads)    
: Review Article | Subject: Adults Hematology & Oncology
Received: 2026/07/23 | Accepted: 2026/09/17 | Published: 2026/09/30
Add your comments about this article : Your username or Email:
CAPTCHA
Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2026 All Rights Reserved | Iranian Journal of Blood and Cancer

Designed & Developed by : Yektaweb